InSite Vision Incorporated (AMEX: ISV) is focused on developing novel ophthalmic products for the treatment of a growing range of common eye problems, including ocular infection, glaucoma, and retinal disease. Their goal as a company is to provide patients and physicians with better treatment options that help preserve and improve vision worldwide. By leveraging their proprietary DuraSite® drug delivery technology, the company is creating alternative ocular anti-infective therapies that may provide substantial advantages over existing treatment options. For further information, visit the Company’s web site at www.insite.com.
- 16 years ago
QualityStocks
InSite Vision Incorporated (AMEX: ISV)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Better Choice Company, Inc. (NYSE American: BTTR) Completes Merger with SRx Health, Will Rebrand as SRx Health Solutions Inc.
Better Choice Company (NYSE American: BTTR) announced the closing of its business combination with SRx…
-
Brera Holdings PLC’s (NASDAQ: BREA) S.S. Juve Stabia S.r.l Posts Largest Valuation Percentage Gain; Signals Club’s Growing Competitiveness
Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s…
-
QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”)…